Baker McKenzie Advises Chemomab Therapeutics Ltd. on Merger with Scipher Medicine Corporation

Baker McKenzie guides Chemomab in a stock-for-stock merger with Scipher, valued at $150 million, focusing on advancing Chemomab’s anti-CCL24 antibody for rheumatoid arthritis, pending approvals by late 2026.